NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

RegulatoryPrimeCPositive

AI Analysis

Summary

NeuroSense filed a U.S. patent application covering PrimeC for traumatic brain injury, including concussion, blast-related injury and CTE. The filing positions the ALS-focused drug for potential expansion into an indication with no approved disease-modifying therapy.

Outcome Details

Filed U.S. patent application seeking protection for PrimeC use in concussion, blast-related brain injury and CTE

Importance:4/10

Sentiment:

0.40

patenttraumatic brain injuryCTEALSPrimeCpipeline expansionneurology

Related Companies

$NRSNW

Read the original article

Published by PR Newswire Pharma on October 19, 2026 12:25 PM

Read Original